Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
Real-time Quote. Real-time Tradegate - 09/19 03:59:57 pm
66.755 EUR   +0.84%
02:56pAnimal health sector aims to emulate Zoetis biotech leap
RE
06:18aBiotech is going to the dogs - and big profits await
RE
09/17BAYER : Invests $20 Million in U.S.-Based Informed Data Systems
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The company is one of the best yield companies with high dividend expectations.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's earnings releases usually do not meet expectations.
  • Analysts covering the stock have recently lowered their earnings forecast.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
BAYER AG9.31%68 298
JOHNSON & JOHNSON0.48%344 174
ROCHE HOLDING LTD.14.65%241 967
MERCK AND COMPANY8.65%212 562
PFIZER-16.66%201 220
NOVARTIS15.63%197 665
NOVO NORDISK AS15.58%121 196
AMGEN0.19%116 966
ASTRAZENECA18.29%113 760
SANOFI6.03%111 125
ABBVIE-22.69%105 372
ELI LILLY AND COMPANY-2.59%103 188
GLAXOSMITHKLINE10.45%101 735
BRISTOL-MYERS SQUIBB COMPAN..-4.08%81 559
CELGENE CORPORATION53.96%69 932
ALLERGAN PLC24.20%54 453
More Results
Financials (EUR)
Sales 2019 46 036 M
EBIT 2019 7 933 M
Net income 2019 3 131 M
Debt 2019 37 298 M
Yield 2019 4,25%
P/E ratio 2019 21,3x
P/E ratio 2020 13,8x
EV / Sales2019 2,17x
EV / Sales2020 2,04x
Capitalization 62 388 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes